Skip to main content

Please enter a keyword and click the arrow to search the site

Takeda: The governance of strategic transformation (A)

Subject

Management Science and Operations

Publication Year

2018

Abstract

The case series describes strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry doyen has narrowed its strategic focus from six to three therapeutic areas, reorganised its global R&D footprint around one Japanese and two US sites, and engaged in over 180 new partnerships across multiple modalities of drug discovery around the world. The pipeline of new drugs, a key gauge of future growth, has shifted from 7% partner-based pre-transformation to approximately 45% partner-based today, and an entrepreneurial, geocentric way of working has taken hold. At Takeda, a generation’s worth of strategic transformation has been compressed into three years.From the outset of the transformation process, outgoing Chairman Yasu Hasegawa and incoming CEO Christophe Weber made it a point to sound out major shareholders and engage candidly with the union, working with different stakeholders to find novel organisational solutions. Once plans crystallised in 2016, Hasegawa and Weber moved to reconstitute the board of directors, changing its composition and renegotiating its modus operandi to further strategic dialogue. During the course of the same year, the executive team was recast around people – internal and external – who had the skills and the mindset to take the company forward on its new path. Early in 2017, executives finally initiated a review and adjustment of existing structures in R&D, particularly as they pertained to the burgeoning partnership portfolio. In other words, Takeda stands out not only as a rare example of a large company reinventing itself, but also as a case that illustrates the importance of proactively addressing the governance of transformation.

Topic List

Corporate governance, Organisational development, Research and development, Strategic transformation

Industry

Pharmaceuticals

LBS Case Number

CS-18-24

Location

Japan

Available on ECCH

No


Select up to 4 programmes to compare

Select one more to compare
×
subscribe_image_desktop 5949B9BFE33243D782D1C7A17E3345D0

Sign up to receive our latest news and business thinking direct to your inbox

×

Sign up to receive our latest course information and business thinking

Leave your details above if you would like to receive emails containing the latest thought leadership, invitations to events and news about courses that could enhance your career. If you would prefer not to receive our emails, you can still access the case study by clicking the button below. You can opt-out of receiving our emails at any time by visiting: https://london.edu/my-profile-preferences or by unsubscribing through the link provided in our emails. View our Privacy Policy for more information on your rights.